European Biopharmaceutical Review |
 |
|
|
|
|
 |
| |
|
|
|
|
New Viral Trend
As this issue goes to press, the world is focused on the challenges posed by a novel coronavirus – SARS-CoV-2. EBR Industry Advisor, Emile Bellott, offers his thoughts and prayers.
|
|
|
|
|
Eschewing the Escalation of Salaries as Safety Professionals Grow Scarcer
Alan White at Arriello
Qualified PV professionals are proving particularly hard to hang on to as demand for experienced safety talent soars. As such, it seems like a good time to look beyond financial remuneration as the key to keeping valued staff motivated and loyal.
|
|
|
|
Transforming Cell and Gene Therapy Trial Design and Execution
Martin Lachs at ICON plc
With over 400 dedicated CGT professionals globally, ICON has developed tools and best practices to transform CGT trial design and execution
|
|
|
|
Next-Generation Sequencing – Where We’ve Been and Where We’re Headed
Mirna Jarosz at Integrated DNA Technologies
Tracking the progress made through DNA sequencing in treating once uncurable health conditions may help us realise the untapped potential of sequencing.
|
|
|
|
Patient-Centric Designs: A Likely Tipping Point for Biosimilar Adoption
George I’ons at Owen Mumford Pharmaceutical Services
Recent opportunities have arisen for biosimilar manufacturers to take hold of the pharma market; however, there are a number of challenges they should be aware of if they wish to properly utilise these opportunities
|
|
|
|
|
|
Bridging the Gap in Personalised Medicine with CAR T Cell Therapies
Filippo Petti at Celyad
CAR T cell therapy holds a lot of potential in terms of serving as a viable treatment for cancer, and an alternative for standard treatment. However, there is still research to be done before any definitive statements are made.
|
|
|
|
Overcoming the Remaining Hurdles
Dr Patrick Laroche at Janssen Oncology EMEA
Though still in its infancy, CAR T cell therapy has already presented with a great deal of potential; however, it would be wise to keep in mind all the obstacles that still need to be overcome for that potential to be reached.
|
|
|
|
Computational Algorithms and Large- Scale Data for CAR T Cell Therapy Resistance
Dr Raul Elgueta, Dr Aida Moreno-Moral, and Dr Rodrigo Santos at Mogrify
CAR T cell therapy has already broken new ground in treatment for cancer patients, and largescale omics data integration and computational analyses are bound to shape the new generation of CAR T cells
|
|
|
|
|
|
Unlocking the Potential of Checkpoint Inhibitors – The Challenge for the Next Decade
Marisol Quintero at Highlight Therapeutics
Immunotherapy is an exciting weapon against cancer but many patients fail to benefit. Scientists are increasingly focused on maximising the potential of the immune system for everyone, perhaps in combination with one of the oldest cancer treatments: radiotherapy.
|
|
|
|
Overcoming First- Generation Shortcomings in Cancer Therapies
Alexis Peyroles at OSE Immunotherapeutics
Immunotherapy is a field of cancer research that has had an impressive level of growth, and continues to present a level of promise that may prove game changing in research and treatment.
|
|
|
|
|
|
50 Years of Pain Management
C Norman Shealy and Sergey Sorin at Shealy-Sorin Wellness Institute
From cranial electrical stimulation to pulsed electromagnetic field therapy, pain management has advanced exponentially over the last 50 years.
|
|
|
|
The Science Is Stacking Up for Regenerative Medicine
Simon Checkley at The Regenerative Clinic
Numerous global studies are under way to evidence the outcomes of orthobiologics and mesenchymal stem cells.
|
|
|
|
|
|
The Trials and Tribulations of CDMOs
Dámaso Molero, CEO of 3P Biopharmaceuticals, talks with EBR about the role, challenges, and future possibilities of CDMOs.
|
|
|
|
Deploying the Full Drug Development Armory to Overwhelm Complex Chemistry
Dr Jingyang Zhu, Dr Ke Chen, and Dr Sam Tadayon at WuXi STA, a WuXi AppTec Company (STA Pharmaceutical)
The demand for more diverse technologies in pharma and biotechnology can no longer be ignored, and CDMO companies are having to adjust accordingly.
|
|
|
|
|
|
Monoclonal Antibodies and Beyond
Michael Foley at AdAlta
Although mAbs have proven to possess exceptional therapeutic properties in many disease areas, there are some limitations that have led to the development of alternative biological scaffolds
|
|
|
|
Antibody Internalisation Assays
With breakthroughs in molecular engineering and antibody humanisation, antibody-based drugs are one of the fastest growing classes of biopharmaceuticals for multiple clinical indications.
|
|
|
|
|
|
.jpg)
